Laparoscopic laterally extended endopelvic resection procedure for gynecological malignancies

Objectives Pelvic side wall infiltration by gynecological malignancies has been considered for a long time an absolute contraindication to curative resection. The development of the laterally extended endopelvic resection (LEER) has challenged this surgical paradigm. Although the LEER has been standardized in open surgery, only small studies have been published about its endoscopic feasibility. The objective of this study is to analyze the safety of LEER in patients with gynecological malignancies involving the pelvic side wall. Methods We retrospectively evaluated a consecutive series of patients who underwent a laparoscopically modified LEER between July 2014 and November 2018. This indicated gynecological tumors involving the pelvic sidewall and surgeries were conducted in two Italian institutions. All patients underwent pre-operative CT scan or PET to evaluate for distant metastases. Patients without suspicioun of distant metastasis underwent pelvic MRI and examination under anesthesia to establish the resectability of the disease and concomitant diagnostic laparoscopy to exclude intraperitoneal dissemination. All women with disease-free interval <6 months, and/or performance status >2 ECOG were excluded. Type of resection was defined based on the status of the pathologic margins: R0, microscopically negative (free margin <5 mm); R1, microscopically positive; and R2, macroscopically (grossly) positive. Disease-free survival was calculated from the date of primary surgery to the time of recurrence. Overall survival was defined as the time from primary surgery to death. Results Overall, 39 patients underwent a laparoscopic LEER and 18 (46.2%) patients were eligible for a laparoscopic approach. Laparoscopic LEER was performed as primary treatment for newly diagnosed tumors in eight patients (44.4%), and for recurrences in the other 10 patients (55.6%). No laparotomic conversions were registered. R0 resection was achieved with negative margins in all patients. The median operative time was 415 min (range, 285–615), median estimated blood loss was 285 mL (range, 100–600), and the median length of hospital stay was 10 days (range; 4–22). Only four patients (22.2%) needed blood intraoperative transfusion. In seven patients (38.9%), post-operative admission to intensive care unit was required. There were three (16.7%) intraoperative complications, all managed laparoscopically. In total there were six (33.3%) major postoperative complications: three patients (16.7%) experienced moderate hydronephrosis with normal renal function, which required temporary placement of nephrostomy; one patient (5.6%) had permanent urinary retention; and two patients (11.1%) had a reoperation, one for post-operative hemoperitoneum and another for complete vaginal cuff dehiscence. Discussion Laparoscopic LEER can be safely performed by experienced laparoscopic surgeons, in carefully selected patients with gynecological malignancies involving the lateral pelvic side wall, even for those in which a bladder and rectum sparing surgery appears possible. Further larger prospective trials are needed to evaluate the oncological and the long-term functional outcomes.

[1]  G. Scambia,et al.  Laterally Extended Pelvic Resection for Gynaecological Malignancies: A Multicentric Experience with Out-of-the-Box Surgery , 2018, Annals of Surgical Oncology.

[2]  J. Sehouli,et al.  Laparoscopic Neuronavigation for Deep Lateral Pelvic Endometriosis: Clinical and Surgical Implications. , 2018, Journal of minimally invasive gynecology.

[3]  V. Gebski,et al.  Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer , 2018, The New England journal of medicine.

[4]  H. Kanao,et al.  Laparoscopic laterally extended endopelvic resection (LEER) for cervical carcinoma recurring at the pelvic sidewall after concurrent chemoradiotherapy: Our experience in three cases. , 2018, Gynecologic oncology.

[5]  L. Horn,et al.  Extended mesometrial resection (EMMR): Surgical approach to the treatment of locally advanced cervical cancer based on the theory of ontogenetic cancer fields. , 2017, Gynecologic oncology.

[6]  G. Scambia,et al.  Out-of-the-box pelvic surgery including iliopsoas resection for recurrent gynecological malignancies: Does that make sense? A single-institution case-series. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  L. Horn,et al.  Surgical treatment and histopathological assessment of advanced cervicovaginal carcinoma: A prospective study and retrospective analysis. , 2017, European journal of cancer.

[8]  S. Marnitz,et al.  Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study , 2015, International Journal of Gynecologic Cancer.

[9]  M. Höckel Long-Term Experience with (Laterally) Extended Endopelvic Resection (LEER) in Relapsed Pelvic Malignancies , 2015, Current Oncology Reports.

[10]  Jane M. Young,et al.  Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. , 2015, Journal of pain and symptom management.

[11]  S. Marnitz,et al.  Morbidity After Pelvic Exenteration for Gynecological Malignancies: A Retrospective Multicentric Study of 230 Patients , 2014, International Journal of Gynecologic Cancer.

[12]  L. Horn,et al.  (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy. , 2012, Gynecologic oncology.

[13]  L. Horn,et al.  Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy. , 2012, Gynecologic oncology.

[14]  L. Horn,et al.  Ontogenetic anatomy of the distal vagina: relevance for local tumor spread and implications for cancer surgery. , 2011, Gynecologic oncology.

[15]  G. Priore,et al.  An Atlas of Gynecologic Oncology : Investigation and Surgery , 2011 .

[16]  L. Horn,et al.  Vulvar field resection: novel approach to the surgical treatment of vulvar cancer based on ontogenetic anatomy. , 2010, Gynecologic oncology.

[17]  L. Horn,et al.  Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis. , 2009, The Lancet. Oncology.

[18]  S. Marnitz,et al.  Indications for primary and secondary exenterations in patients with cervical cancer. , 2006, Gynecologic oncology.

[19]  M. Höckel Ultra-radical compartmentalized surgery in gynaecological oncology. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  M. Höckel,et al.  Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. , 2006, The Lancet. Oncology.

[21]  L. Horn,et al.  Association between the mesenchymal compartment of uterovaginal organogenesis and local tumour spread in stage IB-IIB cervical carcinoma: a prospective study. , 2005, The Lancet. Oncology.

[22]  M. Höckel Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. , 2003, Gynecologic oncology.

[23]  M. Friedlander,et al.  Guidelines for the treatment of recurrent and metastatic cervical cancer. , 2002, The oncologist.

[24]  M. Höckel Laterally extended endopelvic resection: surgical treatment of infrailiac pelvic wall recurrences of gynecologic malignancies. , 1999, American journal of obstetrics and gynecology.

[25]  J. Horiot,et al.  A glossary for reporting complications of treatment in gynecological cancers. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.